Unique investment opportunities in functional personalized oncology
At PreComb, we are dedicated to rapidly deploy the 3DTwin® technology in the realm of personalized medicine, and setting a new standard for functional personalized oncology. Our goal for the next 5 years is to increase our testing capacity by tenfold and extend our international clinical partnerships throughout Europe, the US, and Asia. By leveraging new investments and synergies, we can advance our technology and significantly accelerate the functional personalized medicine market. Please don’t hesitate to contact us for investment opportunities.
Current investors of PreComb
Precomb has received support from distinguished international early-stage investors:
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an
international network of partners, HTGF has already helped forge more than 600 start-ups since 2005.
Kinled is a privately owned investment holding company in the life sciences, digital and financial technology industries. The Vienna-based company has sister offices in London, Shanghai, Hong Kong, and Berne and has direct investments in over 100 companies, as well as being a founder shareholder in the Central European Biotechnology Incubator &
Accelerator at the University of Vienna.
FiveT Capital is a privately held Swiss investment management and holding company specializing in equity linked investment strategies in life sciences and renewable energy. Through its subsidiaries, FiveT Capital offers a wide range of asset management products and tailored financing solutions.
LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health. Its portfolio companies are deploying AI to find new treatments for chronic illnesses, developing SaaS tools to accelerate life-changing medical research and more.